Nanotechnology Now - Press Release: Standard & Poor's Initiates Factual Stock Report Coverage on Starpharma Holdings, Ltd.

Home > Press > Standard & Poor's Initiates Factual Stock Report Coverage on Starpharma Holdings, Ltd.

Abstract:
Standard & Poor's announced today that it has commenced Factual Stock Report coverage on Starpharma Holdings, Ltd.

Standard & Poor's Initiates Factual Stock Report Coverage on Starpharma Holdings, Ltd.

New York, NY | Posted on May 10th, 2007

Starpharma Holdings, Ltd. (OTCQX:SPHRY) develops dendrimer nanotechnology for pharmaceutical, life science and other applications. Starpharma is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc. in Michigan. Products based on Starpharma's dendrimer technology are on the market in the form of diagnostic elements and laboratory reagents.

The company's lead development candidates are based on dendrimer nanotechnology. Dendrimers are man-made, nano-sized compounds with unique properties that make them useful to the health and pharmaceutical industry as both enhancements to existing products and as products that are entirely new.

SPHRY's lead pharmaceutical development product is VivaGel (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of sexually transmitted infections, including HIV and genital herpes. In February 2007, VivaGel was undergoing human expanded safety trials in Melbourne, Australia; San Francisco; and Kisumu, Kenya.

On October 23, 2006, Starpharma acquired Dendritic Nanotechnologies, Inc., which provides innovative dendrimer technologies and commercialization services with its new proprietary Priostar dendrimer technologies. With the acquisition of Dendritic Nanotechnologies, the company gained access to PrioFect, a new application of dendrimer technology.

This report will also be accessible on an ongoing basis to the investment community ---- scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts.

####

About Standard & Poor's Factual Stock Reports
This Standard & Poor’s service provides factual research coverage enabling information about Starpharma Holdings, Ltd. and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company’s fundamentals and business prospects. Currently profiling over 1,000 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor’s. Standard & Poor’s Factual Report research has no access to non-public information received by other units of Standard & Poor’s. Standard & Poor’s does not trade on its own account.

Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P’s STARS research) are eligible to obtain this coverage.

About Standard & Poor's

Standard & Poor's, a division of The McGraw-Hill Companies (NYSE: MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 7,500 employees, including wholly owned affiliates, located in 21 countries, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions.

For more information, please click here

Contacts:

Starpharma Holdings, Ltd.
Ben Rogers, 61 3 8532 2702

or
Standard & Poor's
Customer Contact:
Maria Cruz, 212-438-3671

or
Media Relations:
Michael Privitera, 212-438-6679